Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Quixabeira, D C A, Pakola, S, Jirovec, E, Havunen, R, Basnet, S, Santos, J M, Kudling, T V, Clubb, J H A, Haybout, L, Arias, V, Grönberg-Vähä-Koskela, S, Cervera-Carrascon, V, Kerkelä, E, Pasanen, A, Anttila, M, Tapper, J, Kanerva, A, Hemminki, A
Published in Cancer gene therapy (01.12.2023)
Published in Cancer gene therapy (01.12.2023)
Get full text
Journal Article
Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
Quixabeira, D C A, Jirovec, E, Pakola, S, Havunen, R, Basnet, S, Santos, J M, Kudling, T V, Clubb, J H A, Haybout, L, Arias, V, Grönberg-Vähä-Koskela, S, Cervera-Carrascon, V, Pasanen, A, Anttila, M, Tapper, J, Kanerva, A, Hemminki, A
Published in Cancer gene therapy (01.11.2023)
Published in Cancer gene therapy (01.11.2023)
Get full text
Journal Article
1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Pakola, S.A., Jalkanen, K., Alanko, T.V., Clubb, J.H.A., Quixabeira, D.C.A., Jirovec, E., Kudling, T., Arias, V., Korpisaari, R., Jaakkola, M., Kononen, J.T., Sormunen, J., Pellinen, T., Haybout, L., Kistler, C., Sorsa, S., Havunen, R., Santos, J.M., Cervera-Carrascon, V., Hemminki, A.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma
Monberg, T.J., Kudling, T., Albieri, B., Pakola, S., Ellebaek, E., Donia, M., Eefsen, R.L., von Buchwald, C., Kistler, C., Santos, J.M., Clubb, J., Haybout, L., Westergaard, M.C.W., Quixabeira, D.C.A., Jirovec, E., Havunen, R., Sorsa, S., Cervera-Carrascon, V., Hemminki, A., Svane, I.M.
Published in Immuno-oncology technology (01.08.2024)
Published in Immuno-oncology technology (01.08.2024)
Get full text
Journal Article
50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Quixabeira, D.C.A., Pakola, S., Jirovec, E., Basnet, S., Santos, J.M., Kudling, T., Clubb, J., Haybout, L., Arias, V., Grönberg-Vähä-Koskela, S., Havunen, R., Cervera-Carrascon, V., Pasanen, A., Tapper, J., Kanerva, A., Hemminki, A.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article
48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial
Monberg, T.J., Pakola, S., Dreno, B., Cervera-Carrascon, V., Ellebæk, E., Donia, M., Khammari, A., Kistler, C., Manuel Dos Santos, J., Clubb, J., Haybout, L., Albieri, B., Kudling, T., Quixabeira, D.C.A., Jirovec, E., Havunen, R., Juteau, S., Sorsa, S., Hemminki, A., Svane, I-M.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article